Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 14/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 5/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 5/20 | 0.44 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375194 | 0.89 | IGF1R (0.45) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1374680 | 0.82 | IGF1R (0.52) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1371469 | 0.78 | IGF1R (0.49) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1372583 | 0.78 | IGF1R (0.52) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL4288025 | 0.77 | IGF1R (0.52) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL4278038 | 0.77 | NTRK1 (0.56) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1372764 | 0.77 | IGF1R (0.47) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL12640248 | 0.76 | IGF1R (0.52) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL4278208 | 0.76 | NTRK1 (0.70) | IGF1RNTRK1NTRK3NTRK2CCNA2 | |
| SCHEMBL1371236 | 0.75 | NTRK1 (0.51) | IGF1RNTRK1NTRK3NTRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461193-B2 | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-06-11 | — | — | US | disclosed |
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.I. (IT) | 2011-11-24 | — | — | US | disclosed |
| US-7968583-B2 | Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-06-28 | — | — | US | disclosed |
| US-20090163503-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2009-06-25 | — | — | US | disclosed |
| EP-1963326-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.r.l. (IT) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007068637-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163503-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K5, MAP3K19, MAP3K3 | IGF1R 737/4885NTRK1 1363/4885NTRK3 1220/4885 |
| US-20110288088-A1 | SUBSTITUTED PYRROLO-PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | MAP3K5, MAP3K19, MAP3K3 | IGF1R 737/4885NTRK1 1363/4885NTRK3 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.